ENMEDIA Explores talks with diagnostic company Veracyte’s former CSO and CMO Dr. Giulia Kennedy and Dr. Bernard Peperstraete, the CEO of AcuamarkDx, an early detection and monitoring company.
They say cracking early cancer detection could take liquid biopsy from an $8B market to an $80B market. And they may have the solution for how to do it.
